Aventis Ketek Will Return To FDA Advisory Committee Jan. 8

FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet